Free Trial

Context Therapeutics Q4 2023 Earnings Report

Context Therapeutics logo
$1.01 +0.03 (+3.23%)
As of 01/17/2025 04:00 PM Eastern

Context Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Context Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Context Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Context Therapeutics Earnings Headlines

Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital
2025: Crypto Opportunities You Can’t Afford to Miss
Cryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX), a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

View Context Therapeutics Profile

More Earnings Resources from MarketBeat